Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead radioligand therapy targeting fibroblast activation protein (FAP) and to expand its drug discovery pipeline.
The round was co-led by M Ventures, Hadean Ventures, Sofinnova Partners and 4BIO Capital, with further backing from Bioqube Ventures, Surveyor Capital, Arkin Bio Ventures II and others.
Based in Oslo and Cambridge, Actithera is pioneering a next-generation radioligand therapy (RLT) platform focused on tumour-specific drug retention. Its three-pillar design integrates rational drug design and radiochemistry, targeting longer tumour residence time while reducing systemic exposure.
The platform has yielded a FAP-targeting radioligand candidate with best-in-class potential. It achieves strong tumour specificity and an optimal pharmacokinetic profile, offering improved precision, safety and therapeutic effect.
Dr Andreas Goutopoulos, founder and CEO, brings more than 25 years of experience and previously led discovery efforts at EMD Serono. As Entrepreneur-in-Residence at M Ventures, he supported several oncology-focused biotechs.
Dr Goutopoulos said: “This oversubscribed Series A, backed by a truly global and experienced investor syndicate, is strong validation of our approach. We engineer our radioconjugates for extended retention within tumors, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients.”
Incoming board member Karl Naegler, Partner at Sofinnova Partners, said: “Actithera is applying Big Pharma discipline to an emerging field with enormous potential. Its radioligand therapies represent a meaningful shift in oncology.”
Additional board members include Roger Franklin from Hadean Ventures, Therese Liechtenstein from 4BIO Capital and Debbie Dumont from Bioqube Ventures. They join existing board member Noga Yerushalmi of M Ventures.
